Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease

Pharmacogenomics Journal

Volumn 2, Issue 6, 2002, Pages 383-399

  Peterson, R L ^a   Wang, L ^a   Albert, L ^b   Marchese, E ^c   Erickson, J ^d   Wong, A ^d   Mounts, W M ^a   Hayes, L ^d   Bouchard, P ^e   Keith, J ^b   Dorner, A J ^a  

^a PFIZER INC   (United States)

^b Inflammation Biology and Hemophilia   (United States)

^c Thermo Fisher Scientific   (United States)

^d Investigative Pathology   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

IBD; IL 11; Oligonucleotide array

Indexed keywords

CYTOKINE; GROWTH FACTOR; HLA B27 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT INTERLEUKIN 11;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CLINICAL FEATURE; COLON MUCOSA; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFECT; DRUG MECHANISM; ENTERITIS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HISTOLOGY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL; UNINDEXED SEQUENCE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HLA-B27 ANTIGEN; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-11; MALE; PHARMACOGENETICS; RATS; RATS, INBRED F344; RATS, MUTANT STRAINS; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 12244295506     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500137     Document Type: Article

References (71)

1. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63: 1099-1112.
2. Keith Jr JC, Albert L, Sonis ST, Pfeiffer CJ, Schaub RG. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1994; 12(Suppl 1):79-90.
3. Peterson RL, Wang L, Albert L, Keith Jr JC, Dorner AJ. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 1998; 78: 1503-1512.
4. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 1999; 13: 1307-1315.
5. Trepicchio WL, Bozza M. Pedneault G, Dorner AJ. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996; 157: 3627-3634.
6. Lentsch AB, Crouch LD, Jordan JA, Czermak BJ, Yun EC, Guo R et al. Regulatory effects of interleukin-11 during acute lung inflammatory injury. J Leuko Biol 1999; 66: 151-157.
7. Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 1997; 159: 5661-5670.
8. Redlich CA, Gao X, Rockwell S, Kelley M, Elias JA. IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 1996; 157: 1705-1710.
9. Castagliuolo I, Kelly CP, Qiu BS, Nikulasson ST, LaMont JT, Pothoulakis C. IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol 1997; 273: G333-G341.
10. Bozza M, Bliss JL, Dorner AJ, Trepicchio WL. Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T Cells. J Interferon Cytokine Res 2001; 21: 21-30.
11. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith Jr JC, Brinson YS et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102: 115-123.
12. Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MR, Cooke KR et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999; 104: 317-325.
13. Trepicchio WL, Ozawa M, Waiters IB, Kikuchi T, Gilleaudeau P, Bliss JL et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions [published erratum appears in J Clin Invest 2000; 105: 396]. J Clin Invest 1999; 104: 1527-1537.
14. Peterson RL, Bozza MM, Dorner AJ. Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma protein phosphorylation. Am J Pathol 1996; 149: 895-902.
15. Orazi A, Du X, Yang Z, Kashai M, Williams DA. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 1996; 75: 33-42.
16. Fiore NF, Ledniczky G, Liu Q, Orazi A, Du X, Williams DA et al. Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg 1998; 33: 24-29.
17. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117: 58-64.
18. Breban M, Fernandez-Sueiro JL, Richardson JA, Hadavand RR, Maika SD, Hammer RE et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156: 794-803.
19. An SJ, Hansen NJ, Hodel A, Jahn R, Edwardson JM. Analysis of the association of syncollin with the membrane of the pancreatic zymogen granule. J Biol Chem 2000; 275: 11 306-11 311.
20. Edwardson JM, An S, Jahn R. The secretory granule protein syncollin binds to syntaxin in a Ca2(+)-sensitive manner. Cell 1997; 90: 325-333.
21. Rindler MJ, Hoops TC. The pancreatic membrane protein GP-2 localizes specifically to secretory granules and is shed into the pancreatic juice as a protein aggregate. Eur J Cell Biol 1990; 53: 154-163.
22. Hoops TC, Ivanov I, Cui Z, Colomer-Gould V, Rindler MJ. Incorporation of the pancreatic membrane protein GP-2 into secretory granules in exocrine but not endocrine cells. J Biol Chem 1993; 268: 25 694-25 705.
23. Mullock BM, Smith CW, Ihrke G, Bright NA, Lindsay M, Parkinson EJ et al. Syntaxin 7 is localized to late endosome compartments, associates with Vamp 8, and Is required for late endosome-lysosome fusion. Mol Biol Cell 2000; 11: 3137-3153.
24. Burton J, Roberts D, Montaldi M, Novick P, De Camilli P. A mammalian guanine-nucleotide-releasing protien enhances function of yeast secretory protein Sec4. Nature 1993; 6411: 464-467.
25. Burton JL, Burns ME, Augustine GJ, De Camilli P. Specific interactions of Mss4 with members of the Rab GTPase subfamily. EMBO J 1994; 13: 5547-5548.
26. Fujimiya M, Inui A. Peptidergic regulation of gastrointestinal motility in rodents [Review]. Peptides 2000; 21: 1565-1582.
27. Okamoto H. The Reg gene family and Reg proteins: with special attention to the regeneration of pancreatic beta-cells. J Hepatobiliary-Pancreat Surg 1999; 6: 254-262.
28. Giddings SJ, Carnaghi LR. The two nonallelic rat insulin mRNAs and pre-mRNAs are regulated coordinately in vivo. J Biol Chem 1988; 263: 3845-3849.
29. Devaskar SU, Singh BS, Carnaghi LR, Rajakumar PA, Giddings SJ. Insulin II gene expression in rat central nervous system. Regul Pept 1993; 48: 55-63.
30. Giddings SJ, Carnaghi L. Rat insulin II gene expression by extraplacental membranes. A non-pancreatic source for fetal insulin. J Biol Chem 1989; 264: 9462-9469.
31. Giddings SJ, Carnaghi LR. Selective expression and developmental regulation of the ancestral rat insulin II gene in fetal liver. Mol Endocrinol 1990; 4: 1363-1369.
32. Ostertag EM, Kazazian Jr HH. Biology of mammalian L1 retrotransposons. Annu Rev of Genet 2001; 35: 501-538.
33. Braegger CP. Immunopathogenesis of chronic inflammatory bowel disease. Acta Paediatrica 1994; 83(Suppl): 18-21.
34. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitus and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001; 10: 445-456.
35. Selby WS, Janossy G, Mason DY, Jewell DP. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 1983; 53: 614-618.
36. Hirv K, Seyfarth M, Uibo R, Kull K, Salupere R, Latza U et al. Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: associations with HLA-DR and DQ alleles and subclinical markers. Scand J Gastroenterol 1999; 34: 1025-1032.
37. Annese V, Latiano A, Bovio P, Forabosco P, Piepoli A, Lombardi G et al. Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus-a GISC study. Eur J Hum Genet 1999; 7: 567-573.
38. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212-1217.
39. Mayer L, Eisenhardt D, Salomon P, Bauer W, Plous R, Piccinini L. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 1991; 100: 3-12.
40. Hermel E, Monaco JJ. RT1.DMa and RT1.DMb: the rat homologues of H2-DMa and H2-DMb. Immunogenetics 1995; 42: 446-447.
41. Alfonso C, Karlsson L. Nonclassical MHC class II molecules. Annu Rev Immunol 2000; 18: 113-142.
42. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulation gene expression. Oncogene 2000; 19: 2619-2627.
43. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990; 343: 71-74.
44. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994; 368: 551-554.
45. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996; 274: 618-621.
46. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, Balish E et al. normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis and arthritis in HLA-B27/human β2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953.
47. Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980; 2: 712-715.
48. Tan S, Hooi SC. Syncollin is differentially expressed in rat proximal small intestine and regulated by feeding behavior. Am J Physiol Gastrointest Liver Physiol 2000; 278: G308-G320.
49. Hodel A, Edwardson JM. Targeting of the zymogen-granule protein syncollin in AR42J and AtT-20 cells. Biochem J 2000; 350: 637-643.
50. Alavi K, Prasad R, Lundgren K, Schwartz MZ. Interleukin-11 enhances small intestine absorptive function and mucosal mass after intestinal adaptation. J Pediatric Surg 2000; 35: 371-374.
51. Liu Q, Du XX, Schindel DT, Yang ZX, Rescorla FJ, Williams DA et al. Trophic effects of interleukin-11 in rats with experimental short bowel syndrome. J Pediatric Surg 1996; 31: 1047-1051.
52. Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y et al. A novel gene activated in regenerating islets. J Biol Chem 1988; 263: 2111-2114.
53. Kawanami C, Fukui H, Kinoshita Y, Nakata H, Asahara M, Matsushima Y et al. Regenerating gene expression in normal gastric mucosa and indomethacin-induced mucosal lesions of the rat. J Gastroenterol 1997; 32: 12-18.
54. Kazumori H, Ishihara S, Hoshino E, Kawashima K, Moriyama N, Suetsugu H et al. Neutrophil chemoattractant 2 beta regulates expression of the Reg gene in injured gastric mucosa in rats. Gastroenterology 2000; 119: 1610-1622.
55. Johnson LR, McCormack SA, Wang JY. Regulation of gastrointestinal mucosal growth. In: Walsh JH (editor). Gastrin. Raven Press: New York, 1993, pp. 285-300.
56. Fukui H, Kinoshita Y, Maekawa T, Okada A, Waki S, Hassan MS et al. Regeneration gene protein may mediae gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 2000; 115: 1493-1498.
57. Chiba T, Fukui H, Kinoshita Y. Reg protein: a possible mediator of gastrin-induced mucosal cell growth. J Gastroenterol 2000; 35: 52-56.
58. Christa L, Carnot F, Simon MT, Levavasseur F, Stinnakre MG, Lasserre C et al. HIP/PAP is an adhesive protein expressed in hepatocarcinoma, normal Paneth, and pancreatic cells. Am J Physiol 1996; 271: G993-G1002.
59. Playford RJ. Trefoil peptides: what are they and what do they do? J R Coll Physicians London 1997; 31: 37-41.
60. Murphy MS. Growth factors and the gastrointestinal tract. Nutrition 1998; 14: 771-774.
61. Alison MR, Chinery R, Poulsom R, Ashwood P, Longcroft JM, Wright NA. Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol 1995; 175: 405-414.
62. Cook GA, Thim L, Yeomans ND, Giraud AS. Oral human spasmolytic polypeptide protects against aspirin-induced gastric injury in rats. J Gastroenterol Hepatol 1998; 13: 363-370.
63. Tran CP, Cook GA, Yeomans ND, Thim L, Giraud AS. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 1999; 44: 636-642.
64. Taurog JD, Maika SD, Satumtira N, Dorris ML, McLean IL, Yanagisawa H et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev 1999; 169: 209-223.
65. Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med 1993; 178: 1607-1616.
66. Khare SD, Hansen J, Luthra HS, David CS. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. J Clin Invest 1996; 98: 2746-2755.
67. Khare SD, Bull MJ, Hanson J, Luthra HS, David CS. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. J Immunol 1998; 160: 101-106.
68. Boughton-Smith NK, Wallace JL, Morris GP, Whittle BJ. The effects of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br J Pharmacol 1998; 94: 65-72.
69. Greenwood-Van Meerveld B, Tyler K, Keith Jr JC. Recombinant human interleukin-11 modulates mucosal ion transport in the small intestine and colon of normal and HLA-B27 rats in vitro. Lab Invest 2000; 80: 1269-1280.
70. Hill A, Hunter C, Tsung B, Tucker-Kellogg G, Brown E. Genomic analysis of gene expression in C. elegans. Science 2000; 290: 809-812.
71. Fenhalls G, Wong A, Bezuidenhout J, van Helden P, Bardin P, Lukey PT. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun 2000; 68: 2827-2836.